Clinical evaluation of a new controlled-release formulation of naproxen in osteoarthritis and rheumatoid arthritis
| Autor: | M. Willans, Nicholas Bellamy, G. R. Kraag, Boulos Haraoui, P. Ryan, S. Carette, N. J. Ryley, W. W. Buchanan, Denis Choquette, P. Corey, V. N. Khanna, Ménard Ha, A. Fitzgerald, Jean-Pierre Pelletier, J. S. Percy, Anthony S. Russell |
|---|---|
| Rok vydání: | 1988 |
| Předmět: | |
| Zdroj: | Current Medical Research and Opinion. 11:16-27 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1185/03007998809111126 |
| Popis: | SummaryA two-part multi-centre study was carried out to assess the efficacy and tolerability of a new controlled-release (CR) naproxen tablet in the treatment of osteoarthritis and rheumatoid arthritis. Patients already receiving naproxen on a regular basis were first enrolled in a 6-week randomized double-blind trial comparing the controlled-release tablet (750 mg or 1000 mg once-a-day) to the standard marketed tablet (375 mg or 500 mg twice-a-day). At the end of this phase, patients in both treatment groups were eligible to enter the long-term phase involving 28 weeks of open-label treatment with controlled-release naproxen at the previously established dose level (750 mg or 1000 mg once-a-day). A total of 404 patients entered the initial double-blind phase, 320 of whom continued into the open-label phase. Twenty-nine (14%) naproxen patients and 23 (11%) naproxen CR patients were withdrawn prematurely from the double-blind phase, 87 (27%) patients from the open-label phase. Parameters of efficacy and to... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|